ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2012
DNA methylation of circulating DNA: a marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Evolution of the Use of Circulating DNA as a Biomarker in Neoadjuvant Therapy of Breast Cancer.Current oncology (Toronto, Ont.) · 2026Review
- Changes in active DNA demethylation pathway components during neoadjuvant chemotherapy and their prognostic significance in breast cancer.Breast cancer research : BCR · 2026Article
- Epigenetic Therapies and Biomarkers in Breast Cancer.Cancers · 2022Review
- Role of ctDNA in Breast Cancer.Cancers · 2022Review
- Review
- Circulating Cell-Free DNA in Breast Cancer: Searching for Hidden Information towards Precision Medicine.Cancers · 2021Review
- Liquid Biopsy in Breast Cancer.Geburtshilfe und Frauenheilkunde · 2020Article
- Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker.Oncotarget · 2017Review
- Detection of 14-3-3 sigma (σ) promoter methylation as a noninvasive biomarker using blood samples for breast cancer diagnosis.Oncotarget · 2017Review
- Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine.BioMed research international · 2017Review
- Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.Breast cancer research : BCR · 2016Article
- Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers.Breast cancer research : BCR · 2016Review
- Methylated circulating tumor DNA in blood: power in cancer prognosis and response.Endocrine-related cancer · 2016Review
- Use of Percutaneous Sonographically Guided Microwave Ablation Therapy to Treat Inoperable Malignant Liver Tumours.The West Indian medical journal · 2015Article
- Methylated DNA and high total DNA levels in the serum of patients with breast cancer following neoadjuvant chemotherapy are predictive of a poor prognosis.Oncology letters · 2014Article
- Epigenetic changes associated with inflammation in breast cancer patients treated with chemotherapy.Brain, behavior, and immunity · 2014Article
- The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients.International journal of molecular sciences · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identification of biomarkers for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients is of utmost importance in individual tailoring of treatment and save from toxicity due to non-effective drugs. We hypothesized that methylation of circulating tumor-specific DNA may reflect changes in tumor burden in response to chemotherapy and help stratify responders from non-responders. The aim of this study was to evaluate the potential of methylation changes in circulating DNA to monitor treatment response of breast cancer patients. Six consecutive sera samples collected from 30 breast cancer patients undergoing neoadjuvant chemotherapy were analyzed for methylation status of a panel of five genes namely, BRCA1, MGMT, GSTP1, Stratifin, and MDR1. Among these five genes, BRCA1 methylation frequency was different among responders and non-responders groups. The correlation coefficients between total gene methylation with initial chemotherapy and tumor volume reduction were R(2) = 0.8 and R(2) = 0.05 in the responders and non-responders groups, respectively. Our findings warrant further development of this approach for monitoring response in patients undergoing neoadjuvant chemotherapy.
Indexed as
Identifiers
22744714What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.